Bicyclic Heterocylic Derivatives and Methods of Use
    13.
    发明申请
    Bicyclic Heterocylic Derivatives and Methods of Use 审中-公开
    双环异构衍生物和使用方法

    公开(公告)号:US20110130385A1

    公开(公告)日:2011-06-02

    申请号:US13054841

    申请日:2009-07-21

    摘要: The present invention relates to novel bicyclic heterocycle derivatives, pharmaceutical compositions comprising the bicyclic heterocycle derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. R1 is: I, Ia, Ib ou Ic. R2 is alkyl, alkenyl, aryl, cycloalkyl. heterocycloalkyl or heteroaryl, any of which can be optionally substituted with R3; Y is —C(O)—, —S—, —S(O)—, —S(O)2—, —CH2— or —O—, such that if Y is —O— or —S—, then M is other than N and R1 is (Ib);

    摘要翻译: 本发明涉及新的双环杂环衍生物,包含双环杂环衍生物的药物组合物和这些化合物用于治疗或预防过敏,过敏诱发的气道反应,充血,心血管疾病,炎性疾病,胃肠道疾病, 糖尿病,糖尿病并发症,葡萄糖耐量降低或空腹血糖受损。 R 1是:I,Ia,Ib o Ic。 R2是烷基,烯基,芳基,环烷基。 杂环烷基或杂芳基,其中任何一个可以任选被R 3取代; Y是-C(O) - , - S - , - S(O) - , - S(O)2 - , - CH 2 - 或-O-,如果Y是-O-或-S-, M不是N,R1是(Ib);

    Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
    18.
    发明授权
    Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists 失效
    碳链取代的哌啶及其衍生物可用作组胺H3拮抗剂

    公开(公告)号:US07408066B2

    公开(公告)日:2008-08-05

    申请号:US11455873

    申请日:2006-06-19

    摘要: Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH2)q—, —C(═NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula: where ring A is a monoheteroaryl ring; R2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.

    摘要翻译: 公开了下式的化合物或其药学上可接受的盐,其中:M 1和M 3是CH或N; M 2是CH,CF或N; Y是-C(-O) - , - C(-S) - , - (CH 2 CH 2)q - , - C(-NOR 7) / SO 2 - ) - 或-SO 2 1-2。 Z是键或任选取代的亚烷基或亚烯基; R 1是H,烷基,烯基或任选取代的环烷基,芳基,杂芳基,杂环烷基或下式的基团:其中环A是单杂芳基环; R 2是任选取代的烷基,烯基,芳基,杂芳基,环烷基或杂环烷基; 剩余的变量如规范中所定义; 使用所述化合物单独或与其它试剂组合治疗过敏引起的气道反应,充血,肥胖,代谢综合征非酒精性脂肪性肝病,肝脂肪变性,非酒精性脂肪性肝炎,肝硬化,肝细胞癌或认知缺陷障碍的组合物和方法。